No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Based in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech Co., Ltd., established in 1964 and previously known as China Chemical Synthesis Industry Co., Ltd., specializes in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's market reach includes Taiwan and the United States. Their API portfolio encompasses products designed for immunosuppression, oncology, and cardiovascular conditions, in addition to various peptide compounds. Moreover, they manufacture a wide array of bulk pharmaceutical substances for numerous therapeutic applications, including anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular medications, skeletal muscle relaxants, hypolipidemics, antineoplastics, antihyperlipidemics, and immunosuppressants. Complementing its product offerings, Chunghwa Chemical Synthesis & Biotech delivers bespoke research and development as well as contract manufacturing services to both emerging drug developers and established generic pharmaceutical firms.

• Sensorion S.A.
• Neonc Technologies Holdings, Inc.
• vTv Therapeutics Inc.
• Aldeyra The
• Biomea Fusion, Inc.
• Eloxx Pharmaceuticals, Inc.
• TWi Biotechnology, Inc.
• Macrogen, Inc.